IP Library Granted Patent US 9,579,360
Granted Patent B2
US 9,579,360 · App. 13/801,096 · Granted Feb 28, 2017

Methods of treating or preventing periodontitis and diseases associated with periodontitis

Inventors: John D. Lambris (Philadelphia, PA); George Hajishengallis (Philadelphia, PA)
Assignee: The Trustees of the University of Pennsylvania
A61K38/12A61K39/3955G01N33/502G01N2333/4716G01N2800/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,579,360
App. No.
13/801,096
Granted
Feb 28, 2017
Kind
B2
Abstract

The present disclosure describes methods for preventing or treating periodontitis or diseases associated with periodontitis. The present disclosure also describes methods of screening for compounds that can be used to prevent or treat periodontitis or diseases associated with periodontitis.

Claims (12)

1. A method of treating periodontitis in an individual, comprising:

(a) identifying an individual suffering from or at risk of developing periodontitis; and

(b) administering to the individual a composition comprising a pharmaceutically acceptable carrier and a compound that inhibits or blocks C3 expression, activity, or activation, thereby treating the periodontitis;

wherein the composition does not comprise an antibody, and wherein the compound is a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 25.

2. The method of claim 1 , wherein the composition is administered by a method selected from parenteral, intradermal, subcutaneous, oral, nasal, topical, transdermal and transmucosal.

3. The method of claim 2 , wherein the composition is administered to the periodontal pocket of the individual.

4. A method of reducing the amount of Porphyromonas gingivalis and/or the inflammation caused by P. gingivalis in an individual, comprising:

(a) identifying an individual in which reduction in the amount of P. gingivalis is needed or desired; and

(b) administering to the individual a composition comprising a pharmaceutically acceptable carrier and a compound that inhibits or blocks C3 expression, activity, or activation, thereby reducing the amount of P. gingivalis in the individual;

wherein the composition does not comprise an antibody, and wherein the compound is a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 25.

5. The method of claim 4 , wherein the composition is administered by a method selected from parenteral, intradermal, subcutaneous, oral, nasal, topical, transdermal and transmucosal.

6. The method of claim 5 , wherein the composition is administered to the periodontal pocket of the individual.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2014
From: LAMBRIS, JOHN D.; HAJISHENGALLIS, GEORGE
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 032544/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2014
From: LAMBRIS, JOHN D.
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 032095/0212 →
CONFIRMATORY LICENSE Recorded Jan 17, 2014
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 032086/0764 →
Continuity (2)
Provisional Application 61662022 · Jun 20, 2012
Related Publication 20130344082A1 · Dec 26, 2013